StreetInsider.com News Articles

Form 4 ARVINAS, INC. For: Jun 17 Filed by: Cacace Angela M

Thu, 18 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260618/26665993.html

Form 4 ARVINAS, INC. For: Jun 17 Filed by: Cacace Angela M

Thu, 18 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260618/26665993.html

Form 144 ARVINAS, INC. Filed by: Cacace Angela M

Wed, 17 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26657556.html

Form 144 ARVINAS, INC. Filed by: Cacace Angela M

Wed, 17 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26657556.html

Arvinas and Pfizer complete Rigel license deal for vepdegestrant

Tue, 16 Jun 2026 16:33:10 -0400

Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. have completed a license agreement with Rigel Pharmaceuticals, Inc., granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), according to a company statement.

The transaction received early termination of the Hart-Scott-Rodino antitrust waiting period on June 11, 2026, allowing the agreement to take effect. Rigel has made an initial upfront payment of $70.0 million in aggregate to Arvinas and Pfizer, to be distributed evenly between the two parties.

An additional $15.0 million payment from Rigel is contingent on the successful completion of select development and manufacturing transition activities. Arvinas and Pfizer are

Arvinas and Pfizer complete Rigel license deal for vepdegestrant

Tue, 16 Jun 2026 16:33:10 -0400

An additional $15.0 million payment from Rigel is contingent on the successful completion of select development and manufacturing transition activities. Arvinas and Pfizer are

Arvinas and Pfizer complete Rigel license deal for vepdegestrant

Tue, 16 Jun 2026 16:33:10 -0400

An additional $15.0 million payment from Rigel is contingent on the successful completion of select development and manufacturing transition activities. Arvinas and Pfizer are

Arvinas and Pfizer complete Rigel license deal for vepdegestrant

Tue, 16 Jun 2026 16:33:10 -0400

An additional $15.0 million payment from Rigel is contingent on the successful completion of select development and manufacturing transition activities. Arvinas and Pfizer are

Form 8-K ARVINAS, INC. For: Jun 11

Tue, 16 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260616/26654515.html

Form 8-K ARVINAS, INC. For: Jun 11

Tue, 16 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260616/26654515.html

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Thu, 04 Jun 2026 08:00:00 -0400

NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Participation in these programs will support advancement of ARV-102, Arvinas’ investigational, orally bioavailable and brain-penetrant PROTAC designed to specifically target and degrade leucine-rich repeat kinase 2 (LRRK2) for the potential treatment of neurodegenerative diseases, including Parkinson’s disease and

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Thu, 04 Jun 2026 08:00:00 -0400

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Thu, 04 Jun 2026 08:00:00 -0400

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Thu, 04 Jun 2026 08:00:00 -0400

Form 8-K ARVINAS, INC. For: Jun 02

Tue, 02 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260602/26592461.html

Form 8-K ARVINAS, INC. For: Jun 02

Tue, 02 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260602/26592461.html

Arvinas to Present at Jefferies Global Healthcare Conference

Fri, 29 May 2026 16:01:00 -0400

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.

A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives

Arvinas to Present at Jefferies Global Healthcare Conference

Fri, 29 May 2026 16:01:00 -0400

A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives

Arvinas to Present at Jefferies Global Healthcare Conference

Fri, 29 May 2026 16:01:00 -0400

A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives

Arvinas to Present at Jefferies Global Healthcare Conference

Fri, 29 May 2026 16:01:00 -0400

A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives

Form 4 ARVINAS, INC. For: May 21 Filed by: Teel Randy

Fri, 22 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260522/26541867.html

Form 4 ARVINAS, INC. For: May 21 Filed by: Teel Randy

Fri, 22 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260522/26541867.html

Form 144 ARVINAS, INC. Filed by: Teel Randy

Wed, 20 May 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260520/26529670.html

Form 144 ARVINAS, INC. Filed by: Teel Randy

Wed, 20 May 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260520/26529670.html

Arvinas Employees Give Back During Company-wide Impact Day

Mon, 18 May 2026 10:30:00 -0400

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company’s fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities that will make a meaningful difference across the Greater New Haven area and beyond.

“Impact Day is a meaningful reflection of our